Tandem Diabetes Care, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNDM research report →
Range $15.5 – $40
Price Chart
About the company
Tandem Diabetes Care, Inc. , a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set.
- CEO
- John F. Sheridan
- IPO
- 2013
- Employees
- 2,500
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on TNDM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.22B
- P/E
- -23.38
- Fwd P/E
- 399.90
- PEG
- -0.15
- P/S
- 1.09
- P/B
- 8.66
- EV/EBITDA
- -107.34
- Div Yield
- 0.00%
- Gross Margin
- 56.65%
- Op Margin
- -2.35%
- Net Margin
- -4.58%
- ROE
- -35.61%
- ROIC
- -2.74%
Latest fiscal year · YoY change
- Revenue
- $1.01B+7.9%
- Gross Profit
- $530.85M+8.4%
- Op Income
- $-78,122,000
- Net Income
- $-204,710,000-113.2%
- EPS
- $-3.04-106.8%
- OCF Growth
- -140.1%
- FCF Growth
- -694.1%
- 52W High
- $29.65
- 52W Low
- $12.26
- 50D MA
- $17.24
- 200D MA
- $18.79
- Beta
- 1.59
- RSI (14)
- 48
- Avg Volume
- 2.24M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Tandem posted a strong Q3 with record pump shipments, 14% revenue growth, and margin expansion, while also flagging a slower-than-expected pharmacy transition that could pressure 2027 sales.· November 5, 2026
- Q3 revenue rose 14% year over year to $284 million, with pump shipments up 12% to about 33,000.
- Gross margin improved to 57%, nearly 3 points higher year over year, and adjusted EBITDA margin reached 6% for the fifth straight positive quarter.
- U.S. sales grew 9% to $191 million and international sales jumped 26% to $93 million, a quarterly record.
- Pharmacy penetration is progressing but slower than expected: pharmacy was 15% of U.S. sales in Q3, and management now sees 2026 pharmacy mix below prior assumptions.
- Management highlighted progress on Mobi Tubeless, direct international operations, and a planned pivotal study for the fully closed-loop AIDANET system by year-end 2026.
Worldwide revenue increased 14% year over year to $284 million. Pump shipments rose 12% to approximately 33,000, including nearly 23,000 in the U.S. U.S. sales were $191 million, up 9%, and international sales were $93 million, up 26% year over year or 27% in constant currency. Gross margin was 57%, up nearly 3 percentage points year over year, while operating expenses were $163 million, up 4%. Adjusted EBITDA margin was 6% of sales, and the company ended the quarter with $443 million in cash and investments. For full-year 2026, Tandem kept guidance at worldwide sales of $1.065 billion to $1.085 billion, U.S. sales of $730 million to $745 million, international sales of $335 million to $340 million, gross margin of 56% to 57%, and adjusted EBITDA margin of 5% to 6% of annual sales. Management said fourth-quarter pharmacy is expected to be about 15% to 20% of shipments and 8% to 10% of installed-base supplies, representing nearly 15% of U.S. sales, and said sales headwinds from the pharmacy transition could extend into 2027.
John Sheridan framed the quarter as validation of the company’s strategy: expanding access, strengthening the business model, advancing the pipeline, and improving efficiency. He emphasized record sales in pump shipments, early success in pharmacy access, direct international expansion, and the approach to Mobi Tubeless and fully closed-loop automation. His tone was confident and reflective, repeatedly saying the company is well positioned for long-term success and that he is comfortable handing leadership to Jeannette Bankes.
Leigh Vosseller focused on the numbers behind the quarter: revenue of $284 million, gross margin of 57%, adjusted EBITDA margin of 6%, and cash and investments of $443 million. She said U.S. pharmacy reached 15% of U.S. sales, formulary coverage reached about 50% ahead of plan, and net supply ASPs were above $350 per month, closer to $400 currently. She also noted operating expenses of $163 million were up only 4% year over year, with SG&A reflecting commercial investment and R&D flat, while free cash flow was affected by rebuilding infusion set inventory and capital spending for upcoming launches.
Analysts pressed management on why the CEO transition is happening now, the slower-than-expected pharmacy ramp, and the implications for 2027 sales. On pharmacy, Leigh said adoption is progressing more gradually than expected, that 2026 pharmacy mix now looks more like 10% to 12% of pumps and sales, and that the headwind from pharmacy conversion could continue into 2027. Questions on Mobi Tubeless focused on FDA timing, wear locations, and coverage; John said he expects clearance in Q4 and that the team plans to expand wear options after clearance. On the fully closed-loop program, John said the pivotal study should begin in Q4, include 300 to 400 people across type 1, type 2, and adolescents, and support an FDA submission by end of 2027 with market entry in 2028.
The quarter showed that Tandem’s core business is still growing: revenue, shipments, margins, and adjusted EBITDA all improved, while new customer starts returned to growth. Management also pointed to stronger formulary coverage, rising provider participation, international direct-channel gains, and product catalysts like Mobi Tubeless, AutoSoft+, and the fully closed-loop system.
The biggest concern raised was the slower pharmacy transition, which management said is pacing behind its original assumptions and may create sales headwinds into 2027. There is also ongoing supply-set shortage impact into early 2027, plus execution risk around FDA clearance and later rollout of Mobi Tubeless and the fully closed-loop platform. The new CEO transition adds an additional leadership change while several major strategic shifts are still in progress.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.7%
- Shares Outstanding
- 69.79M
- Float Shares
- 63.97M
of shares held by institutions
293 13F filers
Buy/sell ratio 0.55. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TNDM, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Sep 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Sep 22, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Mar 19, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 4, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Aug 5, 24 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 12, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 23, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 23, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 11.77M | ▲ 191.42K |
| Vanguard Group Inc | 7.34M | ▲ 278.04K |
| Vanguard Portfolio Management LLC | 3.86M | ▼ 439.41K |
| First Light Asset Management, LLC | 3.25M | ▼ 131.72K |
| Vanguard Capital Management LLC | 3.04M | ▼ 52.98K |
| Gw&K Investment Management, LLC | 2.90M | ▲ 334.50K |
| State Street Corp | 2.89M | ▲ 37.27K |
| Goldman Sachs Group Inc | 2.56M | ▲ 1.70M |
| Longaeva Partners L.P. | 2.36M | ▲ 2.36M |
| Ubs Group AG | 2.20M | ▲ 1.05M |
| Exoduspoint Capital Management, LP | 2.08M | ▲ 1.39M |
| Millennium Management LLC | 2.07M | ▲ 759.03K |
Held by 332 ETFs
Biggest fund positions in TNDM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 26 | Vosseller Leigh | other | 2,624 |
| Nov 15, 26 | Vosseller Leigh | other | 942 |
| Nov 15, 26 | Vosseller Leigh | other | 1,495 |
| Nov 15, 26 | Vosseller Leigh | other | 537 |
| Nov 15, 26 | Vosseller Leigh | other | 2,624 |
| Nov 15, 26 | Vosseller Leigh | other | 1,495 |
| Nov 15, 26 | Sheridan John F | other | 9,934 |
| Nov 15, 26 | Sheridan John F | other | 5,055 |
| Nov 15, 26 | Sheridan John F | other | 5,983 |
| Nov 15, 26 | Sheridan John F | other | 3,045 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TNDM coverage
Recent articles, reports, and earnings notes.
Want a deeper read on TNDM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Tandem: Wait Out The 2027 Transition Before Chasing The Turnaround
seekingalpha.com · Nov 16
Tandem Mobi Becomes Only Insulin Pump Offering Both Tubed and Tubeless Wear Options
benzinga.com · Nov 13
Tandem Mobi Now FDA Cleared as World's First and Only Tubeless AID System with up to Seven Days of Wear
businesswire.com · Nov 13
Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump
businesswire.com · Nov 12
What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Tandem Diabetes Care, Inc. (TNDM) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com · Nov 5
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
